# Special Issue

## **Mucosal Immunity and Vaccine**

## Message from the Guest Editors

This Special Issue will focus on the critical role of mucosal immunity in vaccine development, exploring how vaccines can be designed to elicit effective immune responses at mucosal surfaces—the primary entry points for many pathogens. In this Special Issue, original research articles, reviews, short communications, and perspectives are welcome. Topic areas may include (but are not limited to) the following:

- Mechanisms of mucosal immune responses to vaccines.
- Development of mucosal vaccines: oral, nasal, and other routes of administration.
- Comparative efficacy of mucosal versus systemic immunity in infection control.
- Mucosal adjuvants and delivery systems for enhancing vaccine efficacy.
- Role of secretory IgA and other mucosal antibodies in vaccine-induced protection.
- Immune memory and long-term protection conferred by mucosal vaccines.
- Case studies on mucosal vaccines in clinical trials (e.g., for influenza, rotavirus, and HIV).
- Challenges in developing mucosal vaccines for emerging pathogens.
- Computational modeling and bioinformatics in mucosal vaccine design.

We look forward to receiving your contributions.

### **Guest Editors**

Dr. Xingmin Sun

Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B. Downs Boulevard, MDC07, Tampa, FL 33612, USA

Dr. Yongqun He (Oliver)

Unit for Lab Animal Medicine and Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI, USA

### Deadline for manuscript submissions

30 June 2026



## **Vaccines**

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/216440

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

#### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

